Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review

In recent years, we have observed significant progress in cancer treatment associated with the development of immunotherapy. A programmed cell death 1 molecule (PD-1) on the surface of T lymphocytes may be stimulated via a specific PD-ligand 1 (PD-L1), which inhibits lymphocyte activation and leads...

Full description

Bibliographic Details
Main Authors: Marta Dudzińska, Michał Szczyrek, Kamila Wojas-Krawczyk, Joanna Świrska, Izabela Chmielewska, Agnieszka Zwolak
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Cancers
Subjects:
nivolumab
immune-related adverse event
checkpoint inhibitor
non-small cell lung cancer
antithyroid antibody
Online Access:https://www.mdpi.com/2072-6694/12/8/2314

Similar Items

Similar Items